Loading
A phase 1/2 trial of Lapiteronel run by Laekna Limited, terminated.
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT03843918 by Laekna Limited, with 33 participants enrolled, started 2019-04-05, primary completion reached 2023-10-09. Conditions recorded: Prostate Cancer Metastatic. Interventions recorded: LAE001. Reason given for stopping: This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.
Shares Lapiteronel, Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/